277 related articles for article (PubMed ID: 36229464)
21. Impact of cribriform pattern 4 and intraductal prostatic carcinoma on National Comprehensive Cancer Network (NCCN) and Cancer of Prostate Risk Assessment (CAPRA) patient stratification.
Yu Y; Lajkosz K; Finelli A; Fleshner N; van der Kwast TH; Downes MR
Mod Pathol; 2022 Nov; 35(11):1695-1701. PubMed ID: 35676330
[TBL] [Abstract][Full Text] [Related]
22. Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy.
Kweldam CF; Kümmerlin IP; Nieboer D; Verhoef EI; Steyerberg EW; van der Kwast TH; Roobol MJ; van Leenders GJ
Mod Pathol; 2016 Jun; 29(6):630-6. PubMed ID: 26939875
[TBL] [Abstract][Full Text] [Related]
23. Atypical cribriform lesions of the prostate: clinical significance, differential diagnosis and current concept of intraductal carcinoma of the prostate.
Shah RB; Zhou M
Adv Anat Pathol; 2012 Jul; 19(4):270-8. PubMed ID: 22692290
[TBL] [Abstract][Full Text] [Related]
24. Distinction between intraductal carcinoma of the prostate (IDC-P), high-grade dysplasia (PIN), and invasive prostatic adenocarcinoma, using molecular markers of cancer progression.
Dawkins HJ; Sellner LN; Turbett GR; Thompson CA; Redmond SL; McNeal JE; Cohen RJ
Prostate; 2000 Sep; 44(4):265-70. PubMed ID: 10951489
[TBL] [Abstract][Full Text] [Related]
25. Intraductal carcinoma of prostate reporting practice: a survey of expert European uropathologists.
Varma M; Egevad L; Algaba F; Berney D; Bubendorf L; Camparo P; Comperat E; Erbersdobler A; Griffiths D; Grobholz R; Haitel A; Hulsbergen-van de Kaa C; Langner C; Loftus B; Lopez-Beltran A; Mayer N; Nesi G; Oliveira P; Oxley J; Rioux-Leclercq N; Seitz G; Shanks J; Kristiansen G
J Clin Pathol; 2016 Oct; 69(10):852-7. PubMed ID: 26926101
[TBL] [Abstract][Full Text] [Related]
26. Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups.
van Leenders GJLH; Kweldam CF; Hollemans E; Kümmerlin IP; Nieboer D; Verhoef EI; Remmers S; Incrocci L; Bangma CH; van der Kwast TH; Roobol MJ
Eur Urol; 2020 Feb; 77(2):191-198. PubMed ID: 31439369
[TBL] [Abstract][Full Text] [Related]
27. Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer.
Lozano R; Salles DC; Sandhu S; Aragón IM; Thorne H; López-Campos F; Rubio-Briones J; Gutierrez-Pecharroman AM; Maldonado L; di Domenico T; Sanz A; Prieto JD; García I; Pacheco MI; Garcés T; Llacer C; Romero-Laorden N; Zambrana F; López-Casas PP; Lorente D; Mateo J; Pritchard CC; Antonarakis ES; Olmos D; Lotan TL; Castro E
Eur J Cancer; 2021 Apr; 147():74-83. PubMed ID: 33626496
[TBL] [Abstract][Full Text] [Related]
28. PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma).
Shah RB; Shore KT; Yoon J; Mendrinos S; McKenney JK; Tian W
Prostate; 2019 Aug; 79(11):1267-1273. PubMed ID: 31111513
[TBL] [Abstract][Full Text] [Related]
29. Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients.
Seyrek N; Hollemans E; Osanto S; Pelger RCM; van der Poel HG; Bekers E; Bangma CH; Rietbergen J; Roobol MJ; Schoots IG; van Leenders GJLH
Histopathology; 2022 Feb; 80(3):558-565. PubMed ID: 34706119
[TBL] [Abstract][Full Text] [Related]
30. Intraductal carcinoma of the prostate: What we know and what we do not know.
Chen X; Ding B; Zhang P; Geng S; Xu J; Han B
Pathol Res Pract; 2018 May; 214(5):612-618. PubMed ID: 29628124
[TBL] [Abstract][Full Text] [Related]
31. Impact of Cribriform Pattern and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy.
Tom MC; Nguyen JK; Lucianò R; Mian OY; Stephans KL; Ciezki JP; Smile TD; Wei W; McKenney JK; Magi-Galluzzi C; Tendulkar RD
J Urol; 2019 Oct; 202(4):710-716. PubMed ID: 31059665
[TBL] [Abstract][Full Text] [Related]
32. [SIGNIFICANCE OF INTRADUCTAL CARCINOMA OF THE PROSTATE IN POST-OPERATIVE BIOCHEMICAL RECURRENCE].
Sakamoto N; Ueda S; Mizoguchi H; Kawahara I; Kobayashi T; Hamaguchi M; Yoshikawa M
Nihon Hinyokika Gakkai Zasshi; 2017; 108(1):5-11. PubMed ID: 29367511
[TBL] [Abstract][Full Text] [Related]
33. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
Roobol MJ; Verbeek JFM; van der Kwast T; Kümmerlin IP; Kweldam CF; van Leenders GJLH
Eur Urol; 2017 Jul; 72(1):45-51. PubMed ID: 28162815
[TBL] [Abstract][Full Text] [Related]
34. MRI-detectability and histological factors of prostate cancer including intraductal carcinoma and cribriform pattern.
Mikoshi A; Miyai K; Hamabe F; Edo H; Ito K; Matsukuma S; Tsuda H; Shinmoto H
Prostate; 2022 Mar; 82(4):452-463. PubMed ID: 34964158
[TBL] [Abstract][Full Text] [Related]
35. Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P).
Zhu S; Zhao J; Nie L; Yin W; Zhang Y; Zhao F; Ni Y; Zhang X; Wang Z; Dai J; Liu Z; Chen J; Zeng Y; Wang Z; Sun G; Liang J; Zhao X; Zhu X; Tao R; Yang J; He B; Chen N; Shen P; Zeng H
BMC Med; 2022 Jul; 20(1):237. PubMed ID: 35864546
[TBL] [Abstract][Full Text] [Related]
36. Prostate Biopsy Specimens With Gleason 3+3=6 and Intraductal Carcinoma: Radical Prostatectomy Findings and Clinical Outcomes.
Khani F; Epstein JI
Am J Surg Pathol; 2015 Oct; 39(10):1383-9. PubMed ID: 26076065
[TBL] [Abstract][Full Text] [Related]
37. The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performance.
Kato M; Hirakawa A; Kobayashi Y; Yamamoto A; Ishida R; Sano T; Kimura T; Majima T; Ishida S; Funahashi Y; Sassa N; Fujita T; Matsukawa Y; Yamamoto T; Hattori R; Gotoh M; Tsuzuki T
Prostate; 2019 Jul; 79(10):1065-1070. PubMed ID: 31025722
[TBL] [Abstract][Full Text] [Related]
38. Prognostic parameter for high risk prostate cancer patients at initial presentation.
Kato M; Kimura K; Hirakawa A; Kobayashi Y; Ishida R; Kamihira O; Majima T; Funahashi Y; Sassa N; Matsukawa Y; Hattori R; Gotoh M; Tsuzuki T
Prostate; 2018 Jan; 78(1):11-16. PubMed ID: 29094384
[TBL] [Abstract][Full Text] [Related]
39. Intraductal Carcinoma of the Prostate on Diagnostic Needle Biopsy Predicts Prostate Cancer Mortality: A Population-Based Study.
Saeter T; Vlatkovic L; Waaler G; Servoll E; Nesland JM; Axcrona K; Axcrona U
Prostate; 2017 Jun; 77(8):859-865. PubMed ID: 28240424
[TBL] [Abstract][Full Text] [Related]
40. Role of Magnetic Resonance Imaging Targeted Biopsy in Detection of Prostate Cancer Harboring Adverse Pathological Features of Intraductal Carcinoma and Invasive Cribriform Carcinoma.
Prendeville S; Gertner M; Maganti M; Pintilie M; Perlis N; Toi A; Evans AJ; Finelli A; van der Kwast TH; Ghai S
J Urol; 2018 Jul; 200(1):104-113. PubMed ID: 29408568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
